UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 204, 2013

ACCENTIA BIOPHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Florida

(State or Other Jurisdiction of
Incorporation)

000-51383

(Commission File Number)

04-3639490

(I.R.S. Employer

Identification No.)

324 South Hyde Park Avenue, Suite 350

Tampa, Florida 33606

(Address of Principal Executive Offices; Zip Code)

Registrant’s telephone number, including area code: (813) 864-2554

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ACCENTIA BIOPHARMACEUTICALS, INC.

FORM 8-K

Item 5.02. Departure of Directors or ~~Principal~~Certain ~~Officer~~Officers; Election of Directors.

Effective on ~~February~~March 204, 2013, the Company and the Company’s Board of Directors accepted the retirement and resignation of ~~Samuel S.~~Douglas ~~Duffey, Esq~~W. Calder from his employment with the Company~~. Mr. Duffey’s retirement represents the resignation from all positions held by Mr. Duffey with the Company~~, including Vice President, ~~Chief~~Strategic ~~Executive~~Planning ~~Officer,~~& ~~Principal~~Capital ~~Executive Officer, and General Counsel~~Markets. Mr. ~~Duffey~~Calder served without a formal employment agreement and accordingly, his retirement and resignation will not result in any severance compensation or benefits. The resignation described above was voluntary and did not result from any disagreement with the Company known to an executive officer of the Company on any matter relating to the Company’s operations, policies or practices.

~~Effective~~Item ~~as of February 20, 2013, Garrison J~~8.01 Other ~~Hasara, C~~Events.P.A. was appointed to serve in the position of Acting Chief Executive Officer, along with his current positions as, Acting Chief Financial Officer, and Controller of the Company. In addition, Mr. Hasara was also designated to serve as the Company’s Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer in connection with dealings with the Company’s independent audit firm and filings with the Securities and Exchange Commission. The Company and Mr. Hasara have not entered into a formal employment agreement and Mr. Hasara shall maintain his current total compensation for services rendered in all capacities. The following is biographical information regarding Mr. Hasara:

~~Garrison~~Effective J.on ~~Hasara~~March ~~(43)~~4, ~~was~~2013, ~~appointed~~the toCompany’s ~~serve~~Board asof ~~our~~Directors ~~Acting~~accepted ~~Chief~~the ~~Financial~~retirement ~~Officer~~ and ~~designated~~resignation toof ~~serve~~Edmund C. asKing ~~our~~from ~~Principal~~his ~~Financial~~service ~~Officer~~to ~~and~~the ~~Principal~~Company, including ~~Accounting Officer in January 2011~~Director, ~~and~~Lead ~~continues to serve as our Controller~~Director, audit acommittee ~~position~~financial ~~that he has held since June 2005. From November 2003 to June 2005~~expert, ~~Mr.~~Chairman ~~Hasara~~of ~~served~~the asAudit ~~our Compliance Specialist. Prior to that time~~ Committee and ~~prior~~his tomemberships ~~joining~~on ~~our~~the ~~Company,~~Audit ~~from 2000 to 2003~~Committee, ~~Mr. Hasara~~Compensation ~~was~~Committee and the ~~Chief~~Nominating ~~Financial~~and ~~Officer~~Governance Committee of ~~Automotive~~the ~~Service~~Board ~~Centers, Inc., a franchisee~~ of ~~Midas, Inc~~Directors. The Inresignation ~~addition,~~described ~~from~~above ~~1996~~was tovoluntary ~~1999,~~and ~~Mr. Hasara~~did ~~served~~not inresult ~~various~~from ~~accounting~~any ~~roles~~disagreement atwith ~~KForce~~the ~~Inc.,~~Company aknown ~~publicly~~to ~~traded~~an ~~staffing~~executive ~~services~~officer ~~company.~~of ~~Mr. Hasara~~the ~~has~~Company ~~been~~on aany ~~licensed~~matter ~~Certified~~relating ~~Public~~to ~~Accountant since 1993 and received his B.S. from~~ the ~~University~~Company’s ofoperations, ~~South~~policies ~~Florida~~or ~~in 1991~~practices.

Effective on March 5, 2013, the Company and the Company’s Board of Directors accepted the resignation of Christopher C. Chapman, M.D. from his service to the Company including Director and his memberships on the Audit Committee, Compensation Committee and the Nominating and Governance Committee of the Board of Directors. The resignation described above was voluntary and did not result from any disagreement with the Company known to an executive officer of the Company on any matter relating to the Company’s operations, policies or practices.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunder duly authorized.

	ACCENTIA BIOPHARMACEUTICALS, INC.



	By:	/s/ Garrison J. Hasara
		Garrison J. Hasara, CPA Acting Chief Executive Officer, Acting Chief Financial Officer and Controller

Date: ~~February~~March 227, 2013

Filing Compare · ACCENTIA BIOPHARMACEUTICALS INC